alglucerase


Also found in: Wikipedia.

alglucerase

 [al-gloo´ser-ās″]
a modified form of the enzyme lacking in Gaucher's disease, used in treatment of the adult form of the disease.

alglucerase

/al·glu·cer·ase/ (al-gloo´ser-ās″) a form of β-glucocerebrosidase used to replace glucocerebrosidase (glucosylceramidase) in the treatment of the adult form of Gaucher's disease.

alglucerase

A modified form of beta-glucerebrosidase that catalyses the hydrolysis of glucocerebroside in reticuloendothelial system lysosomes, which is the most effective therapy for type-1 Gaucher disease, resulting in decreased hepatospenomegaly, haematologic defects, increased bone mineralisation and reversal of cachexia seen in these patients.

alglucerase

Ceredase® A monomeric 497 AA glycoprotein and modified form of β-glucerebrosidase, which catalyzes the hydrolysis of glucocerebroside in reticuloendothelial system lysosomes, which is produced by genetic engineering; alglucerase is the most effective therapy for type 1 Gaucher disease, resulting in ↓ hepatospenomegaly, hematologic defects, ↑ bone mineralization, and reversal of cachexia Cost Very high. See Gaucher disease, 'Orphan drug. '.
References in periodicals archive ?
The treatment has been related to a reduced risk of spontaneous abortion in women treated with alglucerase and/or imiglucerase, reduced risk of Gaucher-related complications during delivery, and a reduced risk of Gaucher-related complications during the postpartum period (11).
Imiglucerase and alglucerase are generally well tolerated in Gaucher patients and have an excellent safety record (18).
Even when during breastfeeding, the enzyme was likely to be digested in the child's gastrointestinal tract suggesting minimal risk to infants (24), a continued healthy development of children breastfed by alglucerase or imiglucerase treated mothers has been reported (25).
Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepa-topulmonary syndrome.
This therapy uses either imiglucerase or alglucerase, both of which are forms of the enzyme glucocerebrosidase.
r-GCR is expected to be a second generation product of the biopharmaceutical, Ceredase(R) alglucerase injection, approved by the FDA in April 1991.